These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29122359)

  • 21. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
    Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
    Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints.
    De Felice F; Martinetti MT; Orelli S; Bulzonetti N; Musio D; Tombolini V
    Oncology; 2018; 94(1):25-30. PubMed ID: 28918425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.
    Gauthé M; Richard-Molard M; Rigault E; Buecher B; Mariani P; Bellet D; Cacheux W; Lièvre A
    BMC Cancer; 2018 Apr; 18(1):417. PubMed ID: 29653564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy.
    Banerjee R; Roxin G; Eliasziw M; Joseph K; Maclean A; Buie WD; Doll C
    Dis Colon Rectum; 2013 Sep; 56(9):1036-42. PubMed ID: 23929012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
    Linge A; Schötz U; Löck S; Lohaus F; von Neubeck C; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Bunea H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Lauber K; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Krause M; Belka C; Baumann M;
    Radiother Oncol; 2018 Apr; 127(1):27-35. PubMed ID: 29295747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV L1 capsid protein detection and progression of anal squamous neoplasia.
    Hernandez J; Elahi A; Siegel E; Coppola D; Riggs B; Shibata D
    Am J Clin Pathol; 2011 Mar; 135(3):436-41. PubMed ID: 21350099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma.
    Richter I; Jirasek T; Dvorak J; Cermakova E; Bartos J
    Neoplasma; 2016; 63(3):435-41. PubMed ID: 26925790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal.
    Bazan JG; Koong AC; Kapp DS; Quon A; Graves EE; Loo BW; Chang DT
    J Nucl Med; 2013 Jan; 54(1):27-32. PubMed ID: 23236018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
    Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.
    Kochhar R; Renehan AG; Mullan D; Chakrabarty B; Saunders MP; Carrington BM
    Eur Radiol; 2017 Feb; 27(2):607-617. PubMed ID: 27090113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
    Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
    Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group.
    Bonin SR; Pajak TF; Russell AH; Coia LR; Paris KJ; Flam MS; Sauter ER
    Cancer; 1999 Mar; 85(6):1226-33. PubMed ID: 10189126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.
    Fraunholz I; Rödel C; Distel L; Rave-Fränk M; Kohler D; Falk S; Rödel F
    Radiat Oncol; 2012 Jun; 7():88. PubMed ID: 22697293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
    Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
    Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.